|
September 18 - 20, 2013 | Explore innovative models for advancing the translation of novel neurotechnologies, such as neurostimulation, brain-computer interfaces, and neuron replacement therapies, into diagnostic tools and treatments for neurological and psychiatric disease. More
Major depression is a devastating illness; current therapies based on monoamine neurotransmitters are beneficial for only one in ten patients. This eBriefing reviews a paradigm shift in treatment that targets the glutamatergic neurotransmitter system More
A broad look at the methods, impact, and cultural relevance of neuroscience and music . More
-
September 18 - 20, 2013
Explore innovative models for advancing the translation of novel neurotechnologies, such as neurostimulation, brain-computer interfaces, and neuron replacement therapies, into diagnostic tools and treatments for neurological and psychiatric disease.
Monday, May 6, 2013 | 8:15 AM - 4:00 PM
Speakers: Kurt R. Brunden (University of Pennsylvania), Grant J. Carr (AMRI), Gabriela Chiosis (Memorial Sloan-Kettering Cancer Center), Jerold Chun (The Scripps Research Institute), Bonnie M. Davis (Synaptec), Chad Dickey (University of South Florida), Frank E. Koehn (Pfizer Global R&D), David J. Newman (National Cancer Institute, NIH), Salvatore Oddo (University of Texas Health Science Center, San Antonio), Giulio Maria Pasinetti (Mount Sinai School of Medicine)
Alzheimer's disease may benefit from the novel chemistries found in natural products. This conference explores drug discovery from natural products, including novel approaches and technologies, and promising Alzheimer's drug discovery programs.
April 3 - 4, 2013
Organizers: Maureen Black (University of Maryland), Kathryn Dewey (University of California at Davis), Lia Fernald (University of California at Berkeley), Sally McGregor (University College London), Ted Wachs (Purdue University), Susan Walker (University of the West Indies), Aisha Yousafzai (Aga Khan University), Mandana Arabi (The Sackler Institute for Nutrition Science)
This conference will investigate evidence about integrating interventions for optimal early childhood development. Speakers will discuss methods, timing, measurement, scaling up and other topics during interactive sessions with the audience.
Monday, March 25, 2013 | 12:00 PM - 4:00 PM
Organizers: Robert Martone (Covance Biomarker Center of Excellence), Harald Murck (Covance Neuroscience Medical and Scientific Services), Jennifer Henry (The New York Academy of Sciences)
Speakers: Ron Duman (Yale University), Guosong Liu (Tsinghua University, China), Jorge Quiroz (Roche), Simone Sartori (University of Innsbruck, Austria), Carlos Zarate (National Institute of Mental Health, NIH)
Major depression is a devastating illness; current therapies based upon monoamine neurotransmitters are beneficial for only one in ten patients. This program reviews a paradigm shift in treatment targeting the glutamatergic neurotransmitter system.
Wednesday, March 20, 2013 | 12:00 PM - 4:00 PM
Speakers: Ben Philpot (University of North Carolina, Chapel Hill), Tim Roberts (The Children's Hospital of Philadelphia), Stephan Sanders (Yale University School of Medicine), Laurence Tecott (University of California, San Francisco), Paul Wang (Seaside Therapeutics)
Explore recent breakthroughs in early detection of autism and promising therapeutic interventions. This symposium features presents updates on the genetic landscape, the use of mouse models to explore behavior and potential therapeutic biomarkers.
|
-
eBriefing
Organizers: Robert Martone (Covance Biomarker Center of Excellence), Harald Murck (Covance Neuroscience Medical and Scientific Services), and Jennifer Henry (The New York Academy of Sciences)
Speakers: Ronald S. Duman (Yale University School of Medicine), Guosong Liu (Tsinghua University, China), Jorge Quiroz (Roche), Simone B. Sartori (University of Innsbruck, Austria), and Carlos A. Zarate (National Institute of Mental Health, NIH)
Major depression is a devastating illness; current therapies based on monoamine neurotransmitters are beneficial for only one in ten patients. This eBriefing reviews a paradigm shift in treatment that targets the glutamatergic neurotransmitter system.
Annals
Edited by George R. Uhl (National Institutes of Health, Baltimore, Maryland)
The fifth installment of this Annals series presents scholarly reviews on clinical, molecular, pharmacologic, imaging, genetic, and therapeutic aspects of addiction.
Volume 1282
eBriefing
Organizer: Mandana Arabi (The New York Academy of Sciences)
Keynote Speakers: Francesco Branca (World Health Organization), Jean-Pierre Habicht (Cornell University), and Robert E. Black (Johns Hopkins University)
This eBriefing presents the Sackler Institute's Global Research Agenda for Nutrition Science, developed in collaboration with the World Health Organization and global nutrition experts.
eBriefing
Organizers: Rudolph Tanzi (Massachusetts General Hospital and Harvard Medical School), George Zavoico (MLV), and Jennifer Henry (The New York Academy of Sciences)
Speakers: Robert A. Cherny (The Florey Institute of Neuroscience and Mental Health, Australia), Steven M. Hersch (Massachusetts General Hospital and Harvard Medical School), Rudolph Tanzi (Massachusetts General Hospital and Harvard Medical School), and Daniel Tardiff (Whitehead Institute for Biomedical Research)
Transition metals including Fe, Zn, and Cu affect neurotransmission and are implicated in Parkinson's, Huntington's, and Alzheimer's diseases. This eBriefing reviews mechanisms for restoring the physiological balance of these metals in the brain.
Podcast
September 10, 2010
Can we all be wise old owls? Science journalist Stephen Hall and neuroscientist Andre Fenton dissect what we call wisdom, from the neurons in our brain, to the social constructs behind it.
With our economy a shambles and our environment threatened, is there any reason to be optimistic about the future? Matt Ridley says there's scientific proof to say we should be.
What attracts us to a mate? Is "chemistry" really to blame for love at first sight? Biological anthropologist Helen Fisher explains the science behind our mating preferences.
Evolutionary psychologist David Buss explains the mating rituals and patterns of our quirky species. We might not have colorful peacock tails, but we've got some fancy strategies of our own to make up for it.
Translational Medicine Initiative
 The Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.
Learn more at www.nyas.org/TransMed.
|
|
|